Sarah Elizabeth Wakeman, M.D.
This page shows the publications co-authored by Sarah Wakeman and Susan Regan.
Emergency Department-initiated Buprenorphine and Referral to Follow-up Addiction Care: A Program Description. J Addict Med. 2021 Jun 17.
A hospital-wide initiative to redesign substance use disorder care: Impact on pharmacotherapy initiation. Subst Abus. 2020 Dec 03; 1-8.
Impact of Inpatient Addiction Consultation on Hospital Readmission. J Gen Intern Med. 2021 07; 36(7):2161-2163.
The prevalence of unhealthy alcohol and drug use among inpatients in a general hospital. Subst Abus. 2020; 41(3):331-339.
Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use. J Subst Abuse Treat. 2021 03; 122:108248.
The effectiveness of post-discharge navigation added to an inpatient addiction consultation for patients with substance use disorder; a randomized controlled trial. Subst Abus. 2020 Sep 03; 1-8.
Use of promethazine, gabapentin and clonidine in combination with opioids or opioid agonist therapies among individuals attending a syringe service program. Int J Drug Policy. 2020 Apr 21; 79:102752.
Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence. J Addict Med. 2019 Jul/Aug; 13(4):253-257.
Effect of Integrating Substance Use Disorder Treatment into Primary Care on Inpatient and Emergency Department Utilization. J Gen Intern Med. 2019 06; 34(6):871-877.
Vitamin D deficiency exacerbates UV/endorphin and opioid addiction. Sci Adv. 2021 Jun; 7(24).
Perceived risk, attitudes, and behavior of cigarette smokers and nicotine vapers receiving buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. Drug Alcohol Depend. 2021 01 01; 218:108438.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.